good Kim, morning, you, and Thank everyone.
dialing is phone. Khursheed the on who for Vice site, Dr. our and today Q&A initiate portion recent a are his Dr. President investigator Joining Celsion’s the hope cell an Borys, attending will the for a cell on Study call results Chief Church, Chief is to to few who me in review Financial phone. OVATION by Officer, Medical And Jeffrey Officer. Anwer financial and Celsion’s Executive provide of is minutes. way Anwer, by Also Dr. is Nicholas I in it,
you hope stay we Khursheed, So, connected.
little a cold, I apologize if you to a can hear it. going have I’m bit.
do I’ll my best here. So
that development for execution pleasure methodical GEN-X. to ThermoDox our you, clinical possible been the we as approach a particularly programs conclusive of it’s the and with speaking rigorous now have be milestones, made always, As by and
will already. call over be year: not most probable; mostly but that. been a of public remarks the as going domain our start I’m I’ve reassuring, with heard prepared say the me regularly possible that Today’s to making past are in you’ve comment
We the regarding interim This our We’ve or also has at past the III the to remarks. that year of anticipated guidance. a next just now probability X first X by for analysis, OPTIMA analysis my Phase June There a now. and or you of stand higher so success guidance our in that out that said short for point months there interim is year, higher second is been by from probability Study. I’ll
I overall, will you fundamentals again team. no surprises our this And you sound. remind are from management expect that should once
meetings various with resulted regulatory in Our issues. no agencies significant have
manufacturing is Our solid. strategy
cost product is enviable. Our
the unquestioned experts. strategy by trial clinical is Our
Our solid spending cash to Board, XXXX. focused. is OPTIMA both that’s Committee, operating a any of underpinned has of Studies and investigational Data positive that our runway our first X Monitoring position, the blockbuster DMC, X are our independent cash Data measure. Monitoring OVATION Safety sufficient respectively for by products And and been both potential have recommendations by standard tight the management the independent from and or Recent market position an DSMB, into sufficient, been quarter and or support
will note and financing transformative cover be expected during more ability also our to report his the call. funds in strategy, current that are for I’ll this additional could position, that detail time-period on this our cash during developments access our Jeff company.
there. has some that our upfront great acknowledge of undue deal suggest to a pressure, stock want I been reason. defies I out that So under There’s misinformation
misunderstanding purposely some of posted, you and I mostly. some some suspect, speculation As know, probably
Commission, our filings our you Celsion quarterly our the and Exchange and this on trials releases. and company, the your comes information from calls of offer that conference our in press I’d Securities source best with
And be Celsion. the to the year for you I’ll potential has pivotal remind XXXX that
to important our formal which commitment value. like cover to my X shareholder most we’ll is remarks, themes. it, The elaborate I’d important X, that On of and number is
me say positioned again, to the start with are our one. first I’d achieve let to So, like well objectives. we
We the personnel, years. the manufacturing the technology, capability to continue have and relationships, deliver, over past have been few capital as we resources, to doing
are excellent repeat I Our underserved drug commercial directed have potential. lead markets. product and candidates our lead candidates to that, large
studies Second, promise. our clinical showing are
Study the protocol. the the unanimous Monitoring survival a first that and of X, Committee according recommendation As un-blinded from resulted we announced interim data the to by safety in the Data on continue Study November review OPTIMA
recommendation As successful I are a have study. you is accompanying We ignore that the the is My signals, that the otherwise. blinded conclude purposely the also earlier, believe to this data and published expected. of science view predictive a said evidence that had we to pool
XXX-patient progression-free for example, identically, PFS followed that that we a the be show survival, X pool if HEAT years. data prospectively subgroup, Study than The of appears for not better group to tracking
me Let that. explain
This prior of following that is driver identified a our of patients with ThermoDox. treating a radiofrequency subgroup not coming a we This group. into a research is from It’s group success prospective ablation retrospective key plus study. the
combination be now We that XX minutes with minimum of ThermoDox. understand to RFA of in a treatment
group in then Virtually of arm active in a and arm. were control a comprised patients arm, Once of minimum identified patients were active we the of established patients the with are half group of a patients control who of the we half the minutes, of that an XX pre-clinically, treated a arm.
these well-balanced, about a I with progress And I years years, prospectively survival and followed than curative more measure RFA we more than subgroup, of time in to over well-balanced had years. standard releases. the overall X you for for large this demonstrated followed of we years, any X Then by X press quarterly death median alone. of That’s if know followed that we talked benefit X.X you’d group, our arm oncology regularly, think every quarter this And mean, for patients X it years.
inhibitors, that disease, kinase advanced other weeks you with to that and as sorafenib XX for approved as HCC, are want little advanced been approved they’ve survival. I remind
any of is measure by magnitude remarkable. standard the of effect So, here
confirmed been findings it’s These lesion patients. to ThermoDox add manuscript, independent the survival lesion on single an all increase intent-to-treat the of review procedure of And are XXX this population, focusing time concluded, they patients, is that, significance. as by NIH, and a that’s you, single available heating have and the the you to improvements
from cancer. in in recently prospective It’s research. Oxford with that release Phase a public X cancer also and our confirmed been researchers studies, liver supported University and with issued And the also among imaging being various reinforced other conducted that’s studies we data by It’s own fluorescence at the pre-clinically England. by in breast press II studies computational on,
the the of to website, are Now to Earth the all and read preclinical evidence members available you’ll medical would Society. on allow the and compelling. skeptic results me, if it’s it even, Yes, and The all even our science, venture I Flat
diagnosed challenge reasons. recently III advanced gaining IV you up also After been difficult that��s us, with variety reported for We and Phase has get and ovarian to it I/II startup, Stage in been cancer, started very our patients that know, GEN-X of is with OVATION with disease, a you’ve newly Study momentum. a a
review that sites. established The by time NIH deal most or our committee, the took a to an of of establish have requirement which of is great independent investigator which initiated site every many a in the requirement, review a new biological committee,
So seeing if well after that startup, be rates plan. that enrollment could in we with, difficult than better very are our now line very not,
first at I study escalation the current Importantly, the is the portion patients of X which the completing independent the of after in Phase Data the Safety study. dose Monitoring XXX randomized mg/m², Board review recommended dose, their
I to the continue. that we screening am green happy light have to prospective a in backlog report patients the for DSMB’s now DSMB after of
and and too. with excited are I the and of them investigators as for trial obviously, potential are meet So we hope potential are you the the about GEN-X, our about regularly, we,
The supply chain. third our is
very the gross taken function the not costs, we’ve ThermoDox chain necessary capacity. matter margins, of function impressive, to competitive be suppliers for cost-efficient or local and the economy. supply ensure as Now, a for redundant and with as Gross market a only a robust margins GEN-X but and no price multiple of ThermoDox both will steps
primarily or income our Southeast costs quite launch. is in disposable down, countries is keeping Asia and successful extremely important China, is HCC where disease Remember, carcinoma, HCC. now, so being of modest, ThermoDox commercial evaluated hepatocellular a to
the margins other our average, of not, [group] intense in average margin we’ve our expect weighted this, a immunotherapy, very I close you on be gross at manufactured an of gross our saying be X-year XXs, for and plasma-based after the GEN-X, interleukin the drugs. gene mediated [ph]. cost So look when at fraction should the will tech-transfer, been if to XX XXs,
combined patients not, at much is amount GEN-X with it treated Patients an as the important. Believe will plasma. is mg/m² the all plasma XX as other of receive of or world. doses XXX enormous This in
order along effective to an So commercial is margin getting the have down cost strategy, with important. gross in
Your chain evaluate supply license for consider tech focused a beginning. is we pharma from critical remind high-quality completing low-cost And that company as and is our And transfer. on now a are you, the opportunity. redundant big to I’ll us
been Now, number it’s in X, sources our on and our is uncompromising. following I glove conducting uncomplicated And Hand of say, value. us, with financing. focus if trials would successful non-dilutive shareholder you’ve commitment to
sitting stock know short great be leverage the excellent to like a to position. instruments Church, clean position. to establish a a owe that on and exchange. right creative for cover cap And a structure. short his through warrants, very stock negotiation to to was used we deal Jeff warrants We worked No We hard our here, no my retire a can convertible that that used
the in X.X%, with remarkable. than challenge biotech for Last That’s short position. you kind micro-cap less reported I of is companies other I look short to company looked, than less that X%. And the interest
side, Capital about line compares line, October. it misunderstanding let line with facility some clear positive million common up. new a our that try This canceled. it this with the for renewed $XX the line. That On There million. Aspire replaces stock in million we to is equity is $XX me Important, $XX we late
the under the company. stock Celsion the is of major to agreement. this to use know facility And to be important fund discretion, timing our sole our this it’s amount mean will It’s that issued I that a alone, intention know at controls judiciously. and
we use to it. judiciously intend evaluate We the conditions. then it will they’re If use and not not right, do market
warrants. tools, financings and that constructive common offensive, and too defensive too us to look at you enter that is to don’t deals for seen avoid these, discounted we We have as warrant talk discounted both to typical the don’t the toxic XX we biotech the with is are be the we sector, micro-cap into many heavily have over recently you as have, if months heavily as of employed will norm one and heavy and heavy coverage Jeff biotech want the want financings all deal micro-cap last This all space. in about death-spiral
smartly Last fully believe but of our up least, use for I interest-only debt, this our clear very The your leverage debt, spending first on I is we years. number debt equity plans. of use uncomplicated to something investment, the of for debt want to venture not our repayment in our debt. accounted
the to sheet. $XX us cash Now, drivers Then will quarter $X sale important the forward we cash enough look give New we our million balance with the It in into in on than quarter. well net XXXX. us including the another $X of more ended operating value million losses, through million through adding Jersey see the current to
biotechnology a to Jersey part got environment. I of pharmaceutical the we say, be New to delighted are
very know Jersey the their kind commercial companies for ahead company the shareholders. certainly the of of You to good Their their incentive our capability of ours and cradle this willingness operating like that good provide industry. sell for for net losses been pharmaceutical to civilization for has New is
that from The be last to is thought make like leaders the reassuring to point the international you. I’d should support
global from fields key and leaders largely in cancer, their We continue of medicine, liver receive support focused to leaders in ovarian cancer. opinion
GEN-X support Requests trials ThermoDox their regularly. of for numerous. We them and are for sort through
capability the interest to going heartening. our a Their in the tumors is it of of deal and on have with variety number very We driven researchers. is of a by that mechanism ThermoDox solid has effectively with results, action, activities
Another is example then presenting interest their of colleagues. medical ThermoDox their in to
Ghassan conference Riccardo of Professor As cosponsored the the University preeminent symposium researchers HCC, Pisa. included Liver and including we Kettering Association Abou-Alfa, Memorial in an in of International focused at from example, a Sloan recently symposium X September. Lencioni of the Cancer HCC on This
HCC. them for well Professor preeminent it was HCC. radiofrequency Lencioni lot I attended; the is expert there, a ablation future in of focusing questions, the treatment great The many program, on for options was of
of promise indication; very, a know with. was Thermodox deal You to very very underserved is difficult explored this The thoroughly. quite
once also us, that template for ThermoDox, to education a medical to the is with note authorization. these but can market of We introducing us prior formal available that kinds data programs provide
it the from we quite we and bit once So trial. positive a learned use have to this intend data from
I’ll data planned. at from as continue the the committee news to efficacy regarding the unblinded that the of pre-specified study The now OPTIMA DMC the unanimously turn interim recommended following a the analysis. Study positive the recommendation from we review first
analysis, this following XXX this reviewed patient of committee which evidence early For of August concern safety occurred the deaths futility or any DMC The data XXXX. study. in issues found in XXX patient no
what mentioned, subgroup events prospective our seen in XXX patient PFS virtually HEAT are that particularly is identically I through is encouraging As Study. earlier tracking the
ThermoDox, say more overall advantage, than with OPTIMA did benefit. the subgroup, trial While, to Study, more months. only not although succeed, I death demonstrated want for HEAT the this X-year a received who minutes XX is that a RFA again, median it survival success time the of final that I’ll for at XX% emphasize survival XX bar to of of analysis, the Study
margin we that So a our of here great have conclude successful. study be to would deal
the when for talk So to prospective I’ll in about a success minute. the ratios compared hazard far lower bar subgroup.
it’s we analysis, in one, company Number not patient first the with consistent meet and at OPTIMA hazard information. interim the with quality observed the demographics expectations, did required data are what Study the subgroup company prospective important. meeting provide ratio did metrics data Although, factors the the risk following very so the
the a for clinical here our life’s high-quality metrics. a quality with of And Dr. and Controlling commitment been the Borys. operations delighted team globally the has quality study metrics, we’re study,
pool two, the to which OPTIMA XX.X-month a data overall, compared blinded progression. Number time median that for Study months. PFS the median the favorably for prospective the pool to data These reached from showed XX.X subgroup,
with deaths HEAT patient to prospective of the Study rate the the Study three, well OPTIMA be subgroup. appears Number for tracking
conclusions. we As mature sufficiently to survival overall any suspected, was not the draw from however, OPTIMA Study
The study follow-up subgroup XX of median had of Study a months. events prospective comparative months, follow-up median follow-up, a a median the whereas the had XX OPTIMA had
So I’d here. suggestion just give you little a
If you’d website. judge XXX on Manuscript. in HEAT look, you marker for the meaningful subgroup take is a encourage prospective capital patients yourself, It’s for separation published I the the our of to occurs. like, where a
to follow-up X% a investigators to about an potential. study And number than loss patient way kind trial. X, patients the results to and properly to year, this less for allowance suggests has the commitment only follow, suggests, study the for lost per to X% that the year. their OPTIMA be with what’s us And was the per and study’s so order in X This patients important of believe in able is of us, designed and evaluate the by
the X.X. The So of our to the observed, success will was subgroup. occur preplanned again observed next ratio minimum following prospective for efficacy events. for a patient XXX hazard XXX hazard of is analysis the compares ratio that favorably This
presentation, our on it’s analysis, Kaplan-Meier X.XX. the is website that at in ratio look you hazard If our corporate
X.X. ratio believe to the with that out an I’ll second interim, also are consistent what the chance what So p-values success odds-on hazard at successful. we the And gives for is be for next interim point
Now the the allowed interim at X.XX. was X.XXXX. it p-value subgroup The be to for the prospective for second p-value is successful
success have p-value. So at hazard a margin for potential interim. that the here the conclude, there ratio some and here, is To with we next both the
the new China, that there cases with HCC recall year. more largest in each Now, diagnosed of XXX,XXX incidence occurs than
patients. ThermoDox In the accelerate the to trial. have it It’s have the it Chinese turn, data my an from and expressed I indicated last As the mentioned on authorities view. interest, I call, in means
up. followed the during to to us was this They there a asked meeting October. in XXXX. able We was be Dr. sooner. Borys We means evaluate if data a This followed with stated past up
for think CFDA. Administration it the The the Drug XX. met for National was as October Evaluation Medical formerly company Director Products the at I the the Center NMPA, or with known
CDE Director and with the team. met the So we of her
at possibility think With accelerated to data encouraging. the But was second interim time. they after analysis, efficacy that a is the from first interim they not which the that analysis, conditional OPTIMA support the sufficient preference approval consider did of trial, the respect data to we or indicated to un-blinding indicate maturity
OPTIMA was we clinical more participate We the sites a compassionate in should use consider company positive, China. Borys’ program direction Even making as are Study. high certainly suggestion they plans in do; the encouraging the in Dr. a quality volume, see that a that launch to made, this and to high program under
saying lives. unique program, extend very patients without compassionate potential goes It the to given a know, provide a their we opportunity use what with to there’s
our quarter, be you X work are goal to and have HCC. we last for wonkies, are mentioned position report the you can to ThermoDox once are the completed. and we of is I quickly on able and who to continuing those modules file The as for us positive I Meanwhile, NDA nearly data. to NDA X
excited very but generated, more we’re exceptionally potential HCC, about only could and believe asset this and for valuable of summary, are tumors. an not In be data as solid ThermoDox the other for
While and interest promise. compelling probably that some investors most equally this point, for immediate we at GEN-X OPTIMA ThermoDox of holds an are and believe
is is of Earlier X, Phase GEN-X in typically evaluated their are patients. heavy and II a Patients Study newly the with diagnosed naïve late-stage stage development, OVATION that X fills in cancer ovarian I/II treatment tumor belly. malignancy being burden that
is we to after similar treated OVATION chemotherapy In them surgery. to And GEN-X. of continue patients in with study with treat which is treat with goal in I, in chemotherapy nature, delay GEN-X to prior OVATION neoadjuvant study, II, we’ll typically with surgery. prior The surgery, following to our They’re this progression. which combination
this answer dose XXX have safety We mg/m². portion, Phase randomized II designed selected should the study Phase end That’s up be year. XXX by the now that that before to I followed to mg/m². is one we the believe of portion, a to, continuation the evaluate I/II of up OVATION will of to
is do randomized The that. open-label were allowed, open-label data trial as investigators to the X:X only happy and from the to an Phase as report become II confident, trial. And we’re
the This designed the using the system, plasma. resulting our DNA our inflammatory or nanoparticle persistent the is in technology. cell secretion protein GEN-X transfected platform with interleukin-XX comprised IL-XX. proprietary be enables lipopolymeric associated with That’s plasma, TheraPlas. plasma, And delivery we TheraPlas DNA of an to of regional cytokine local nanoparticle
IL-XX that malignancies. system the fight know be we to entire And of protein recruiter potent a anticancer immune to
every can it in believe We reason to effective be have ovarian cancer.
reported as we DSMB enrolled independent week, Data safety portion data it; XXX Last Monitoring of to completed total. its Board, from the the in I the Safety was I first X review be calling what will Phase from patients patients
the the study The the enrollment And patients Phase of on proceed the the in I current XXX remaining Based portion portion planned. we will mg/m² to trial as continues receive unanimous GEN-X. in the continue trial. recommendation of with completing this of
In by minimum patients target. control That’s all, patients, a our X yearend. the of arm and we in have should the patients X in GEN-X X arm
that, will followed researchers be cancer translational tissue by once from samples by Roswell Park interrogated data, these Following institute. outcomes and surgical data, objective rates; the we response have at reporting patients been
States. point, XX sites, recruit patients. January add a running and this XX up sites up to in in the X At to Canada for more total United active expect sites we have we of XX will And in
the year. of hopeful I we’ve trial we very complete to are once seen Phase particularly that, And is the backlog end the goal by do the that portion. given in that immediately next reopening Our enrollment we can
the have is events be care when or the study XX% the PFS, of standard have improvement powered alone. at PFS followed a after least least conducted in of care after with endpoint, comparing analysis patients at XX XX show GEN-X observed all for to which whichever been a been The The will to standard is primary later. is months,
GEN-X Again, is prognosis to Also, the their is plus we as patients because patient earlier, receive surgery. GEN-X progression, know here interval after in the arm, delay great. I the progresses, debulking when not a will mentioned goal that chemotherapy
X half to first expected of XXXX. the is in first portions The begin
we arsenal GEN-X finalizing be competitive marketplace force. that optimistic in very both place week for we’re will its and saying our margins by that a find announced will ovarian in we conclude supply and tech the last are mind, ultimately cancer, product and also transfer. the in high-margin treatment I With
one Hainan or global lot, for a Pharma Pharm produced Poly use from first our we in Pharm, lots fact, China. actually In HISUN manufacturers: lot and clinical Poly X from
the to As to expected an GEN-X the I ensure of rapid cost market margins. approved, mentioned, is goal market affordable the for our regardless adoption or treatment gross region. significant and support structure Once is
Now, in positioned it – before over his sheet, that quarter to balance a our call financials. strong developments team. for management to is capital to and to is review a again, coming the emphasize our significant year. of third turn I deliver well I Jeff access to Celsion, want committed Underpinning fundamentals the
value the continue to expect in We to significant community. medical for our shareholders create and patients
Now that, turn I’ll with it Jeff. over Jeffrey? to
